Valor202020212022202320242025TTMGastos comerciales, generales y administrativos88.21 M102.8 M102.46 M76.16 M72.98 M73.54 M73.54 MInvestigación y desarrollo266.95 M438.63 M461.64 M387.33 M320.65 M284.81 M284.81 MBeneficio operativo-354.44 M373.53 M-673.16 M-222.54 M-466.57 M-664.57 M-664.57 MTotal de ingresos no operativos6.38 M6 M22.66 M71.82 M103.9 M86.61 M86.61 MGastos por intereses, netos de intereses capitalizados———————Ingresos no operativos, una vez deducidos los gastos por intereses0000000Ingresos/gastos extraordinarios6.38 M6 M22.66 M71.82 M103.9 M86.61 M86.61 MBeneficio antes de impuestos-348.06 M379.53 M-650.5 M-150.72 M-362.67 M-577.97 M-577.97 MParticipación en los beneficios-5.47 M-5.47 M—————Impuestos809 K1.87 M-325 K2.89 M3.59 M3.63 M3.63 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos-1.86 M—-12.47 M16.55 M38.62 M23.53 M23.53 MBeneficio neto antes de actividades interrumpidas-348.87 M377.66 M-650.17 M-153.61 M-366.25 M-581.6 M-581.6 MOperaciones suspendidas———————Beneficio neto-348.87 M377.66 M-650.17 M-153.61 M-366.25 M-581.6 M-581.6 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-348.87 M377.66 M-650.17 M-153.61 M-366.25 M-581.6 M-581.6 MBeneficio básico por acción-5.294.97-8.36-1.94-4.34-6.47-6.47Beneficio por acción diluido-5.294.7-8.36-1.94-4.34-6.47-6.47Número medio de acciones ordinarias65.95 M75.95 M77.75 M79.22 M84.36 M89.93 M354.24 MAcciones diluidas65.95 M80.39 M77.75 M79.22 M84.36 M89.93 M354.24 MEBITDA-345.25 M391.48 M-648.99 M-202.7 M-447.31 M-645.09 M-645.09 MEBIT-354.44 M373.53 M-673.16 M-222.54 M-466.57 M-664.57 M-664.57 MCosto de los ingresos———————Otros costes de producción———————Amortización y depreciación (flujo de caja)9.18 M17.95 M24.17 M19.84 M19.26 M19.48 M19.48 M
CRISPR Therapeutics AG
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.